TRITON-PN: En undersøgelse til evaluering af effektiviteten og sikkerheden af Nucresiran hos patienter med arvelig transthyretin amyloidose med polyneuropati (TRITON-PN)
TRITON-PN: En fase 3, global, randomiseret, åben-label undersøgelse til evaluering af effektiviteten og sikkerheden af Nucresiran hos patienter med arvelig transthyretin-medieret amyloidose med polyneuropati (hATTR-PN)
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Clinical Trial Information Line
- Telefonnummer: 1-877-ALNYLAM
- E-mail: clinicaltrials@alnylam.com
Undersøgelse Kontakt Backup
- Navn: Clinical Trial Information Line
- Telefonnummer: 1-877-256-9526
- E-mail: clinicaltrials@alnylam.com
Studiesteder
-
-
-
Belgrano, Argentina, C1428AQK
- Rekruttering
- Clinical Trial Site
-
Rosario, Argentina, CP2000
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Darlinghurst, Australien, 2010
- Rekruttering
- Clinical Trial Site
-
Woolloongabba, Australien, 4102
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto, Brasilien, 14051-140
- Rekruttering
- Clinical Trial Site
-
Rio de Janeiro, Brasilien, 22640-100
- Rekruttering
- Clinical Trial Site
-
Rio de Janeiro, Brasilien, 22775-001
- Rekruttering
- Clinical Trial Site
-
Salvador, Brasilien, 40290-000
- Rekruttering
- Clinical Trial Site
-
São Paulo, Brasilien, 04038-002
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Vancouver, Canada, V5Z 1M9
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Égkomi, Cypern, 2371
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
London, Det Forenede Kongerige, NW3 2QG
- Rekruttering
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Rekruttering
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02118
- Rekruttering
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Clinical Trial Site
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Clinical Trial Site
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75246
- Rekruttering
- Clinical Trial Site
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Créteil, Frankrig, 94000
- Rekruttering
- Clinical Trial Site
-
Le Kremlin-Bicêtre, Frankrig, 94270
- Rekruttering
- Clinical Trial Site
-
Marseille, Frankrig, 13005
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Athens, Grækenland, 115 28
- Rekruttering
- Clinical Trial Site
-
Heraklion, Grækenland, 715 00
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Dublin, Irland, D24 NR0A
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Florence, Italien, 50134
- Rekruttering
- Clinical Trial Site
-
Milan, Italien, 20133
- Rekruttering
- Clinical Trial Site
-
Padova, Italien, 35128
- Rekruttering
- Clinical Trial Site
-
Pavia, Italien, 27100
- Rekruttering
- Clinical Trial Site
-
Roma, Italien, 00168
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Bunkyo C, Japan, 113-8519
- Rekruttering
- Clinical Trial Site
-
Kumamoto, Japan, 860-8556
- Rekruttering
- Clinical Trial Site
-
Matsumoto-shi, Japan, 390-8621
- Rekruttering
- Clinical Trial Site
-
Suita, Japan, 565-0871
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Guadalajara, Mexico, 44670
- Rekruttering
- Clinical Trial Site
-
Tlalpan, Mexico, 14080
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Rekruttering
- Clinical Trial Site
-
Porto, Portugal, 4099-001
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Bern, Schweiz, 3010
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Clinical Trial Site
-
Huelva, Spanien, 21005
- Rekruttering
- Clinical Trial Site
-
L'Hospitalet de Llobregat, Spanien, 8907
- Rekruttering
- Clinical Trial Site
-
Madrid, Spanien, 28040
- Rekruttering
- Clinical Trial Site
-
Palma de Mallorca, Spanien, 07198
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Stockholm, Sverige, 113 61
- Rekruttering
- Clinical Trial Site
-
Umeå, Sverige, 907 37
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Seoul, Sydkorea, 06351
- Rekruttering
- Clinical Trial Site
-
Seoul, Sydkorea, 05030
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Rekruttering
- Clinical Trial Site
-
Taipei, Taiwan, 112
- Rekruttering
- Clinical Trial Site
-
Taoyuan City, Taiwan, 33305
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Istanbul, Tyrkiet (Türkiye), 34093
- Rekruttering
- Clinical Trial Site
-
Izmir, Tyrkiet (Türkiye), 35330
- Rekruttering
- Clinical Trial Site
-
-
-
-
-
Berlin, Tyskland, 10117
- Rekruttering
- Clinical Trial Site
-
Heidelberg, Tyskland, 69120
- Rekruttering
- Clinical Trial Site
-
Münster, Tyskland, 48149
- Rekruttering
- Clinical Trial Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Andre navne:
|
|
Aktiv komparator: Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Andre navne:
Vutrisiran 25 mg administered SC q3M
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procentvis reduktion i serum TTR-niveauer i Nucresiran-gruppen sammenlignet med in-studie Vutrisiran-gruppen gennem måned 9
Tidsramme: Op til måned 9
|
Op til måned 9
|
|
|
Procentvis reduktion i serum TTR-niveauer i Nucresiran-gruppen sammenlignet med den inden for studiet Vutrisiran-gruppen gennem måned 18
Tidsramme: Op til måned 18
|
Op til måned 18
|
|
|
Procentuel reduktion i serum TTR-niveauer i Nucresiran-gruppen sammenlignet med in-study Vutrisiran-gruppen ved uge 6
Tidsramme: Uge 6
|
Uge 6
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Medical Director, Alnylam Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ALN-TTRSC04-004
- 2025-522544-40-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .